Clinical Trial

Tracking Triple-negative Breast Cancer Evolution Through Therapy

Study acronym: TRACERX-TNBC
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
A prospective multicentre study which aims to examine the relationship between intratumour heterogeneity (ITH) and pathological response to neoadjuvant chemotherapy in patients with histological confirmation of triple-negative breast cancer (TNBC) who are eligible for neoadjuvant chemotherapy.
Protocol Amendment History 1 change
minor Completion pushed: 2026-05 -> 2026-09-30 2026-08-04
Trial Details
NCT Number NCT03077776
Lead Sponsor UNICANCER
Collaborators: National Cancer Institute, France
Conditions Triple-Negative Breast Neoplasm
Enrollment 149 participants
Start Date 2017-04-14
Primary Completion 2024-06-01 (estimated)
Study Completion 2026-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-03